United States set
Menu Shopping cart $0 Search
Distributed product

Ostase® BAP EIA

  • Regulatory status:FDA
  • Type:Immunocapture enzyme activity assay
  • Other names:bone-specific alkaline phosphatase
  • Species:Human
Cat. No. Size Price

AC-20F1 96 wells $867,08
PubMed Product Details
Technical Data


Immunocapture enzyme activity assay


The Ostase® BAP EIA Assay is an in-vitro device indicated for the quantitative measurement of bone-specific alkaline phosphatase (BAP), an indicator of osteoblastic activity in human serum. This device is intended to be used as an aid in the management of postmenopausal osteoporosis and Paget’s disease. Ostase® is a registered trademark of Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc.

Scientific Description:

Serum levels of BAP are believed to reflect the metabolic status of osteoblasts. An accurate assessment of bone metabolism is critical for determining the severity of metabolic bone disease and responses to therapy. Measurement of serum levels of BAP has been shown to be useful in evaluating patients with Paget’s disease, osteomalacia, primary hyperparathyroidism, renal osteodystrophy, osteoporosis and metastases to bone.



Sample Requirements

50 μL/well


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Range

7-90 μg/L


The kits are CE-IVD certified and intended for professional use.



  • Fast turnaround time – results in approximately half the time of other manual assays. (1h 15 mins. total incubation with <30 mins. hands-on time)
  • Measures bone specific alkaline phosphatase (BAP) with low interference from other alkaline phosphatase isoforms
  • Excellent limit of detection (<1.0 μg/L)
  • Clinically relevant assay range – accommodates samples in a wide dynamic range (7-90 μg/L)
  • Excellent correlation with automated methods

Research topic

Bone and cartilage metabolism

Related Products Docs